Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Congdon, 2003, Important causes of visual impairment in the world today, JAMA, 290, 2057, 10.1001/jama.290.15.2057

1991, Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration, Arch Ophthalmol, 109, 1220, 10.1001/archopht.1991.01080090044025

1999, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials–TAP report 1, Arch Ophthalmol, 117, 1329, 10.1001/archopht.117.10.1329

2001, Am J Ophthalmol, 131, 541, 10.1016/S0002-9394(01)00967-9

Yancopoulos, 2010, Clinical application of therapies targeting VEGF, Cell, 143, 13, 10.1016/j.cell.2010.09.028

Ferrara, 2009, VEGF-A: a critical regulator of blood vessel growth, Eur Cytokine Netw, 20, 158, 10.1684/ecn.2009.0170

Rosenfeld, 2006, Ranibizumab for neovascular age-related macular degeneration, N Engl J Med, 355, 1419, 10.1056/NEJMoa054481

Brown, 2006, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N Engl J Med, 355, 1432, 10.1056/NEJMoa062655

Schmidt-Erfurth, 2011, Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study, Ophthalmology, 118, 831, 10.1016/j.ophtha.2010.09.004

Regillo, 2008, Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1, Am J Ophthalmol, 145, 239, 10.1016/j.ajo.2007.10.004

Boyer, 2009, A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration, Ophthalmology, 116, 1731, 10.1016/j.ophtha.2009.05.024

Singer, 2012, HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration, Ophthalmology, 119, 1175, 10.1016/j.ophtha.2011.12.016

Martin, 2011, Ranibizumab and bevacizumab for neovascular age-related macular degeneration, N Engl J Med, 364, 1897, 10.1056/NEJMoa1102673

Martin, 2012, Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results, Ophthalmology, 119, 1388, 10.1016/j.ophtha.2012.03.053

Chakravarthy, 2012, Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial, Ophthalmology, 119, 1399, 10.1016/j.ophtha.2012.04.015

Economides, 2003, Cytokine traps: multi-component, high-affinity blockers of cytokine action, Nat Med, 9, 47, 10.1038/nm811

Holash, 2002, VEGF-Trap: a VEGF blocker with potent antitumor effects, Proc Natl Acad Sci U S A, 99, 11393, 10.1073/pnas.172398299

Heier, 2011, The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor Trap-Eye dosed as-needed after 12-week fixed dosing, Ophthalmology, 118, 1098, 10.1016/j.ophtha.2011.03.020

Stewart, 2008, Predicted biological activity of intravitreal VEGF Trap, Br J Ophthalmol, 92, 667, 10.1136/bjo.2007.134874

Brown, 2011, Primary endpoint results of a phase II study of vascular endothelial growth factor Trap-Eye in wet age-related macular degeneration, Ophthalmology, 118, 1089, 10.1016/j.ophtha.2011.02.039